ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Synlogic has raised $40 million in its second large financing round, which was led by OrbiMed HealthCare Fund Management and included founding investors Atlas Venture and New Enterprise Associates. Synlogic, which uses synthetic biology to push gut bacteria to sense and repair disease, will use the funds to support two drugs in development. The company hopes to put treatments for urea cycle disorder and phenylketonuria, both rare metabolic diseases, into clinical studies in early 2017. With this latest round, it has brought in $70 million in funding.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter